Subscribe to Newsletter
Business & Profession Legislation & policy, Terpene & residual solvent analysis, Pesticide analysis, Potency testing

Policy Précis

Epidiolex descheduled. For the first time, a cannabinoid medicine (Epidiolex, a CBD-based therapy used to treat Dravet syndrome) has been descheduled by the US DEA. Read the press release from manufacturer GW Pharma here.

EVALI leads to tighter cannabis controls. Oregon officials will carry out random testing for unlicensed additives in cannabis products and Washington State passed an emergency rule banning vape products containing vitamin E acetate. A second rule “requires manufacturers of THC products to disclose all compounds (including ingredients, solvents, additives, etc.) used in the production and processing as well as the sources of all vapor products."

Epidiolex descheduled. For the first time, a cannabinoid medicine (Epidiolex, a CBD-based therapy used to treat Dravet syndrome) has been descheduled by the US DEA. Read the press release from manufacturer GW Pharma here.

EVALI leads to tighter cannabis controls. Oregon officials will carry out random testing for unlicensed additives in cannabis products and Washington State passed an emergency rule banning vape products containing vitamin E acetate. A second rule “requires manufacturers of THC products to disclose all compounds (including ingredients, solvents, additives, etc.) used in the production and processing as well as the sources of all vapor products."

Growing cannabis for research. After a four-year delay, the US DEA has announced it will review 37 applications to grow cannabis for research, and published a draft framework for growers (read it here). US scientists have previously complained that the cannabis supplied by NIDA for research (currently grown at a single facility at the University of Mississippi)  is very different from that on sale in dispensaries. 

What is a “unit” of THC? The NIDA has issued a request for information from researchers to help establish a standard dose of THC (they are proposing 5 mg), which they believe will allow a more systematic study of the benefits and harms of cannabis use. 

Hemp testing reprieve. Following criticism, the USDA delayed the requirement for all hemp testing to be carried out at DEA-registered labs until October 2021, or publication of the final rule, whichever comes first. Read the statement here.

Referendum ready in New Zealand. The latest version of New Zealand's Cannabis Legislation and Control Bill will be put to the nation in a referendum on September 19. The Bill sets out what legalizing personal use for adults would look like, with large fines or jail time for unlawful supply, and a focus on treatment rather than punishment for underage users. 

Lebanon legalizes cultivation. Read more here.

Receive content, products, events as well as relevant industry updates from The Cannabis Scientist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Charlotte Barker

Associate Content Director

After studying biology at Imperial College London, I got my start in biomedical publishing as a commissioning editor for healthcare journals, and I’ve spent my career covering everything from early-stage research to clinical medicine. Attracted by the creativity, talent and passion of the team, I joined Texere Publishing in 2014, where I’m now Associate Content Director and Editor of The Cannabis Scientist.

Register to The Cannabis Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Cannabis Scientist magazine

Register